Overview

The Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid is a clinical risk tool for adults presenting to the emergency department (ED) with suspected acute coronary syndrome (ACS). It was derived to retain the strengths of the original Manchester Acute Coronary Syndromes (MACS) model while removing dependence on heart-type fatty acid binding protein (H-FABP), a biomarker that is not widely available. T-MACS uses one on-arrival measurement of high-sensitivity cardiac troponin T (hs-cTnT) together with six dichotomous clinical variables in a logistic regression equation to produce an individual estimated probability of ACS within 30 days. That probability is then mapped to four prespecified risk bands that were aligned with the original MACS care pathways: very low, low, moderate, and high risk.

The tool is intended as a decision support instrument at the point of first assessment—after an initial ECG interpretation, vital signs, focused history, and the first troponin result—not as a substitute for serial troponin protocols where indicated, specialist cardiology input, or institutional chest-pain guidelines.

Background and rationale

Evaluating chest pain in the ED requires balancing missed myocardial infarction against over-investigation, prolonged observation, and admission. High-sensitivity troponin assays improved the ability to detect myocardial injury early, but numeric troponin values alone have limited specificity for type 1 myocardial infarction because many cardiac and non-cardiac conditions elevate troponin. The MACS investigators previously combined hs-cTnT, H-FABP, and clinical features in a multivariable model that could both “rule out” and “rule in” ACS at defined probability thresholds, with the goal of supporting efficient disposition and resource use.

Because H-FABP testing is not part of routine practice in many hospitals, the same group re-derived the model using only hs-cTnT as the laboratory input—hence the name T-MACS. External validation across multiple UK cohorts suggested that discrimination remained strong and that a substantial proportion of patients could be classified as very low risk (with very high negative predictive value for ACS in those studies) while a smaller fraction met criteria for very high modeled probability.

Outcome definition used in derivation and validation

In the primary analyses underpinning T-MACS, ACS was defined as prevalent acute myocardial infarction (AMI) at the index visit or incident major adverse cardiac events within 30 days, specifically incident AMI, death from any cause, or coronary revascularisation. This composite reflects both immediate diagnostic certainty and short-term hard cardiac outcomes relevant to ED risk stratification.

AMI adjudication followed contemporary troponin-based criteria (rise and/or fall of cardiac troponin with at least one value above the 99th percentile, with clinical evidence of myocardial ischaemia), consistent with guideline-oriented definitions used in the parent studies.

Model inputs: clinical features

Each of the following is coded as present (1) or absent (0) based on data available at arrival, using the same pragmatic definitions as in the MACS family of models:

• ECG ischaemia (E): ischaemic ECG changes on the initial tracing, as judged by the treating clinician. This mirrors real-world use but introduces inter-observer variability, which is an explicit design choice in the original work.
• Worsening or crescendo angina (A): anginal pattern with increasing frequency, onset with less exertion, or longer duration—i.e. an unstable angina phenotype in historical terms.
• Pain radiating to the right arm or shoulder (R): patient-reported radiation of the presenting pain to the right arm or shoulder (a feature retained from the original MACS predictor set).
• Vomiting associated with symptoms (V): vomiting in association with the presenting episode of pain or discomfort.
• Sweating observed (S): diaphoresis noted by the treating clinician at presentation (observed, not only patient-reported).
• Hypotension (H): systolic blood pressure <100 mmHg on arrival to the ED.

Model input: high-sensitivity troponin T

The continuous variable T is the hs-cTnT concentration on arrival, expressed in nanograms per litre (ng/L). The derivation and validation studies used the Roche Diagnostics Elecsys fifth-generation hs-cTnT assay, with performance characteristics and 99th percentile cut-points as reported in the primary publication. The troponin term enters the model as a linear function of concentration (after exploratory checks of functional form in the derivation work).

If your laboratory reports troponin in micrograms per litre (μg/L), multiply by 1,000 to convert to ng/L before applying the published coefficients. Assay- and platform-specific calibration differ; applying T-MACS coefficients to a non-Roche high-sensitivity troponin assay (or to cardiac troponin I) is not supported by the original validation and should be avoided outside dedicated revalidation studies.

Probability calculation

T-MACS estimates the probability p of the primary ACS composite using a standard logistic form. With rounded coefficients as published, the linear predictor (logit) is:

z = 1.713·E + 0.847·A + 0.607·R + 1.417·V + 2.058·S + 1.208·H + 0.089·T − 4.766

and the estimated probability is:

p = 1 / (1 + e^−z)

Implementation is typically done with software (web calculator, electronic health record integration, or handheld device) because small arithmetic errors or unit mistakes materially change risk classification.

Risk bands and pathway logic

The same four probability bands used for MACS were applied to T-MACS outputs:

• Very low risk: p < 0.02. In the original framework, this stratum corresponded to ACS being effectively “ruled out” for pathway purposes, with very high negative predictive value in the reported cohorts. Discharge or ambulatory strategies still require alignment with local protocols, serial testing when appropriate, and reassessment if symptoms evolve.
• Low risk: 0.02 ≤ p < 0.05. Suggested management in the model’s narrative included serial troponin in a lower-acuity area (such as an ED observation unit) and consideration of discharge if repeat biomarkers and clinical status remain reassuring.
• Moderate risk: 0.05 ≤ p < 0.95. This broad intermediate zone implies ongoing inpatient-style evaluation, serial troponin, and consideration of additional testing (functional imaging, computed tomography coronary angiography, or invasive angiography) according to risk, availability, and guidelines.
• High risk: p ≥ 0.95. This threshold was described as “ruling in” ACS for pathway purposes, prompting urgent cardiology-oriented care and ACS-directed therapy pending definitive diagnosis. Positive predictive value for ACS in this stratum was very high in the derivation cohort; validation cohorts showed strong but not identical performance, underscoring the need for clinical correlation.

Reported diagnostic performance (summary)

In the derivation cohort, patients classified as very low risk comprised a substantial minority of the population; negative predictive value for ACS and for prevalent AMI in that stratum was very high, with sensitivity for ACS across the rule-out strategy also very high. In the pooled validation set, a similar proportion fell into the very low category, again with very high NPV for ACS and AMI in that group, at the cost of moderate specificity overall—typical of sensitive rule-out tools embedded in broader populations with chest pain.

At the high-probability end, a smaller fraction of patients met the rule-in threshold; the proportion of true ACS in that group was high in derivation and remained clinically meaningful in validation, though not identical across cohorts. Area under the receiver operating characteristic curve for T-MACS in validation was in the high range, and comparison with the original MACS model showed similar overall discrimination despite dropping H-FABP.

T-MACS was also compared with a simple limit-of-detection style strategy (very low initial hs-cTnT plus no ECG ischaemia) in the validation set: sensitivity for ACS was reported as similar between strategies, while T-MACS classified a larger share of patients into the very-low stratum, reflecting incorporation of additional clinical information beyond troponin alone.

Important caveats for bedside use

• Early presenters: Patients who arrive very soon after symptom onset may have initially negative or low troponin despite evolving infarction; any probability model based on a single draw must be interpreted together with time from symptom onset and repeat sampling per guideline.
• ECG and cohort effects: One external validation cohort excluded patients with ECG ischaemia at presentation by design; extrapolation to populations enriched with ST changes or obvious ischaemia requires caution.
• Elevated troponin without type 1 MI: High modeled probability or high troponin may reflect supply–demand ischaemia, myocarditis, pulmonary embolism, renal dysfunction, sepsis, or other conditions. T-MACS estimates risk of the prespecified ACS composite in studied cohorts, not a definitive label of plaque rupture or occlusive thrombosis.
• Shared decision-making and local policy: Disposition, antithrombotic therapy, and imaging should follow institutional chest-pain pathways, cardiology consultation, and patient preferences—not the model output in isolation.

How this calculator applies the model

This CalcMD tool collects the six binary clinical features and the on-arrival hs-cTnT value (with optional unit conversion), computes the logit and probability using the published rounded coefficients, assigns the corresponding risk band, and displays educational text summarizing typical next-step considerations. It is provided for education and documentation support; it does not store patient identifiers and does not replace real-time clinical judgment or legally binding protocols.